SeraCare SeraSeq TMB gDNA and FFPE Reference Materials
SeraCare Life Sciences has released what it says are the first available genomic DNA and formalin-fixed paraffin-embedded reference materials for tumor mutational burden measurement by next-generation sequencing assays. The company created the new materials as part of its work with the Friends of Cancer Research TMB harmonization working group and the International Quality Network for Pathology's TMB EQA Pilot Program.
Data generated from using the reference samples was presented by FOCR at the 2019 American Society of Clinical Oncology Meeting, and by IQN Path at the 2019 European Congress of Pathology, demonstrating their utility in harmonizing and standardizing measurements of TMB by different NGS assays.
In addition to the new SeraSeq TMB gDNA and FFPE materials available now, SeraCare said it can also create custom tissue and blood-based TMB reference materials through its VariantFlex custom reference material development platform.
Thermo Fisher Scientific Oncomine Comprehensive Assay Plus
Thermo Fisher Scientific has launched the Oncomine Comprehensive Assay Plus for the detection of targeted and immuno-oncology biomarkers. The assay, designed for solid tumors, covers more than 500 genes and enables analysis of both DNA and RNA in a single workflow. It detects single nucleotide variants, indels, copy number variants, gene fusions, and splice variants and is suitable for microsatellite instability (MSI) and tumor mutational burden (TMB) assessment. The assay requires 1 ng DNA/RNA input and fits seamlessly into existing Thermo Fisher Ion Chef and Ion GeneStudio system workflows.
Genome Medical Genome Care Delivery
Genome Medical, a telegenomics technology and services company, has launched Genome Care Delivery, a cloud-based platform that provides hospitals, health systems, and employers virtual access to a nationwide network of clinical genetics specialists in order to expedite and facilitate the delivery of genetic expertise. The platform is initially focused on oncology and reproductive health, and is intended to deliver education, engagement, and access to genetic experts for virtual visits and provider-to-provider consults, as well as genetic wellness assessment and screening for population health management, the company said. Features include curated content, adaptive videos, webinars, online assessment tools, virtual care visits with genetic specialists, personalized recommendations regarding genetic testing, and clinical action plans based on genetic test results and medical management guidelines.
For more new products and services, please visit the New Products page on our website.